DUBLIN–(BUSINESS WIRE)–Sep 9, 2021–
Ophthalmology Pipeline Highlights Database – 2021, provides the most up-to-date information on key pipeline products in the global Ophthalmology Drug market.
It covers emerging therapies for Ophthalmology disorders in active clinical development stages including early and late-stage clinical trials. Key indications covered in this database include Conjunctivitis, Glaucoma, Diabetic Retinopathy, Myasthenia gravis, Dry Eye Syndrome, Age-related Macular Degeneration, and Cataract. The pipeline data is presented in an excel dashboard with filtering options.
The pipeline data presented in this database helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
The database presents pipeline by Ophthalmology indications. Key indications covered in this database include Conjunctivitis, Glaucoma, Diabetic Retinopathy, Myasthenia gravis, Dry Eye Syndrome, Age-related Macular Degeneration, and Cataract.
By Clinical Trial Stages:
The database provides Ophthalmology pipeline products by clinical trial stages including both early and late-stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
By Drug Mechanism Classes:
The database provides Ophthalmology pipeline products by their dominant drug mechanism class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
The database provides Ophthalmology pipeline products by the company.
- Ophthalmology Pipeline by Indication
- Ophthalmology Pipeline by Clinical Trial Phase
- Ophthalmology Pipeline by Drug Mechanism Classes
- Ophthalmology Pipeline by Company
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OPTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 09/09/2021 04:38 PM/DISC: 09/09/2021 04:38 PM